19-Mar-2025 3:30 PM CST - Business Wire Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the
6-Jan-2025 7:30 AM CST - Business Wire Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimers disease (AD). The call will focus on the companys plans t
15-Nov-2024 4:00 PM CST - Business Wire Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimers disease. Alpha Cognition is focused
19-Mar-2025 3:30 PM CST - Business Wire Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the
6-Jan-2025 7:30 AM CST - Business Wire Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), an FDA-approved treatment for mild-to-moderate Alzheimers disease (AD). The call will focus on the companys plans t
15-Nov-2024 4:00 PM CST - Business Wire Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimers disease. Alpha Cognition is focused
